GLSI — Greenwich Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $195.10m
- $187.88m
- 43
- 13
- 70
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -3.43 | -1.86 | -4.57 | -7.83 | -8.89 |
Amortisation | |||||
Non-Cash Items | 0.195 | 0.678 | 0.661 | 1.74 | 2.38 |
Other Non-Cash Items | |||||
Changes in Working Capital | 2.93 | 0.028 | -0.385 | -0.122 | 0.032 |
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -0.293 | -1.15 | -4.29 | -6.2 | -6.48 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.215 | 29.8 | 2.84 | -7.54 | 0 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.078 | 28.7 | -1.46 | -13.7 | -6.48 |